Search

Special pharmaceutical company Mallinckrodt is selling its photopheresis business, Therakos to CVC Capital Partners for $925 million. [ABSTRACT FROM AUTHOR]

Special pharmaceutical company Mallinckrodt is selling its photopheresis business, Therakos to CVC Capital Partners for $925 million. [ABSTRACT FROM AUTHOR]

Mallinckrodt, a pharmaceutical company, has filed an application for the trademark "THERACIDE." The application, made by Kenneth D. Goetz, was made public on November 23, 2023. The trademark is related to a disinfectant formulation for use in cleaning environmental surfaces in the sanitation field. Mallinckrodt is the owner of the application, with the address provided as 675 McDonnell Boulevard P.O. Box 5840, St. Louis MO 63134. This information was reported by NewsRx journalists based in Washington, D.C. [Extracted from the article]

A trademark application has been filed for the name "BARO-CAT" by Mallinckrodt, a pharmaceutical company. The application, submitted by Kenneth D. Goetz, relates to the use of Barium Sulfate Suspension as an X-Ray Contrast Medium. The application was made available to the public on November 23, 2023. Mallinckrodt is the owner of the application, with the address listed as 675 McDonnell Boulevard P.O. Box 5840, St. Louis MO 63134. [Extracted from the article]

Mallinckrodt, a pharmaceutical company, has filed a trademark application for "BEAR E YUM." The application, made by Jeffrey S. Boone on behalf of Mallinckrodt, was made public on November 23, 2023. The trademark application is for a flavored barium sulfate formulation specifically packaged for pediatric use as an aid in X-ray diagnosis of the gastrointestinal tract. The owner of the application is Jeffrey S. Boone, and the company is located in St. Louis, Missouri. [Extracted from the article]

Mallinckrodt, a pharmaceutical company, has filed a trademark application for "SCAN C" for medical preparations used as internal liquid markers for diagnostic X-rays. The application was made by Kenneth D. Goetz and made available to the public on November 23, 2023. The trademark application is classified under international goods and services class code 005. The owner of the application is Mallinckrodt, located in St. Louis, MO. [Extracted from the article]

Mallinckrodt, a pharmaceutical company, has filed an application for the trademark "ENTROBAR" for a barium sulfate contrast medium used in x-ray diagnosis. The application was made by Jeffrey S. Boone and became available to the public on November 23, 2023. Mallinckrodt is the owner of the application, with the address provided as 675 McDonnell Boulevard P.O. Box 5840, St. Louis MO 63134. This information was reported by NewsRx journalists based in Washington, D.C. [Extracted from the article]

A trademark application has been filed for the name "MALLCOSORB" by Mallinckrodt, a pharmaceutical company. The application, submitted by Jeffrey S. Boone, indicates that it is for a carbon dioxide absorbent. The application was made available to the public on November 23, 2023. Mallinckrodt is the owner of the application, with the contact information provided as Jeffrey S. Boone, Mallinckrodt, 675 McDonnell Boulevard P.O. Box 5840, St. Louis MO 63134. [Extracted from the article]

Mallinckrodt, a pharmaceutical company, has filed a trademark application for the name "GASTROMARK" for diagnostic agents used in medical applications. The application was made by Kenneth D. Goetz and made available to the public on November 23, 2023. The trademark application is classified under international goods and services code 005. The owner of the application is Mallinckrodt, located in St. Louis, Missouri. [Extracted from the article]

Mallinckrodt, a pharmaceutical company, has filed a trademark application for the term "LF." The application includes a range of goods and services related to urological and radiographic imaging technology, such as x-ray tables, imaging apparatus, injectors, and contrast media. The application was made public on November 23, 2023, and the owner of the application is Timothy A. Cheatham from Mallinckrodt. This news article provides factual information about the trademark application and does not express any judgments or opinions. [Extracted from the article]

Mallinckrodt, a pharmaceutical company, has filed an application for the trademark "HD 200" for a chemical compound used as a contrast medium in fluoroscopic and x-ray examination of the gastric system. The application was made by Kenneth D. Goetz and made available to the public on November 23, 2023. The trademark application is classified under international goods and services class code 005. [Extracted from the article]

Mallinckrodt, a pharmaceutical company, has filed a trademark application for the name "XENOTRON." The application, made by Jeffrey S. Boone on behalf of Mallinckrodt, was made public on November 23, 2023. The trademark application is for medical apparatus used to transfer xenon gas into delivery devices for administering xenon to patients. The owner of the application is Jeffrey S. Boone, and the company's address is located in St. Louis, Missouri. This news article provides factual information about the trademark application and does not express any opinions or judgments. [Extracted from the article]

A trademark application for "HYDRADJUST" has been filed by Mallinckrodt, a pharmaceutical company. The application, submitted by Jeffrey S. Boone, relates to urological X-ray tables. The application was made available to the public on November 23, 2023. Mallinckrodt is based in St. Louis, Missouri. [Extracted from the article]

Mallinckrodt, a pharmaceutical company, has filed a trademark application for "HD 85" for a chemical compound used as a contrast medium in fluoroscopic and x-ray examination of the gastric-intestinal system. The application was made by Kenneth D. Goetz and made available to the public on November 23, 2023. The owner/registrar information for this application is Kenneth D. Goetz, Mallinckrodt. This information is sourced from a news article that provides fact-based news on research and discoveries in the field of health and medicine. [Extracted from the article]

A trademark application for the name "HYQUAL" has been filed by Mallinckrodt, a pharmaceutical company. The application, submitted by Jeffrey S. Boone, relates to metallic stearate lubricants. The application was made available to the public on November 23, 2023. Mallinckrodt is based in St. Louis, Missouri. [Extracted from the article]

Mallinckrodt, a pharmaceutical company, has filed an application for the trademark "RSN" for the goods and services related to Stearates. The application was made by Jeffrey S. Boone and became available to the public on November 23, 2023. Mallinckrodt is the owner of this application, with the address located in St. Louis, MO. This news article provides factual information about the trademark application and does not express any opinions or judgments. [Extracted from the article]

A trademark application has been filed for the name "TECHNEKOW" by Mallinckrodt, a pharmaceutical company. The application, submitted by Kenneth D. Goetz, relates to the production of a generator of radioactive technetium for clinical use. The application was made available to the public on November 23, 2023. Mallinckrodt is the owner of the application, with their contact information listed as 675 Mcdonnell Boulevard P.o. Box 5840, P.o. Box 5840, St. Louis MO 63134. [Extracted from the article]

A trademark application for the term "HD" has been filed by Mallinckrodt, a pharmaceutical company. The application, submitted by Kenneth D. Goetz, relates to a chemical compound taken orally that is used as a contrast medium in fluoroscopic and x-ray examination of the gastric system. The application was made available to the public on November 23, 2023. The owner and registrar of the application is Kenneth D. Goetz, Mallinckrodt, located in St. Louis, Missouri. [Extracted from the article]

Mallinckrodt, a pharmaceutical company, has filed an application for the trademark "BAROS" for a foaming agent used in the diagnosis of double contrast roentgenography. The application was made by Kenneth D. Goetz and became available to the public on November 23, 2023. The trademark application is classified under international goods and services code 005. The owner and registrar of the application is Kenneth D. Goetz, located at Mallinckrodt in St. Louis, Missouri. [Extracted from the article]

A trademark application for the name "CHEETAH" has been filed by Mallinckrodt, a pharmaceutical company. The application, submitted by Kenneth D. Goetz, relates to a flavored barium sulfate formulation used as an aid for computed tomography of the gastrointestinal tract. The application was made available to the public on November 23, 2023. Mallinckrodt is based in St. Louis, MI. [Extracted from the article]

Sil;ence Therapeutics is snatching back two siRNA drug targets developed through a $20 million collaboration with Mallinckrodt Pharmaceuticals. [ABSTRACT FROM AUTHOR]

The FDA has rejected Mallinckrodt's request for approval of terlipressin in a rare type of progressive kidney failure. Mallinckrodt suffered the setback despite hitting its primary endpoint in phase 3 and winning the backing of an advisory committee in a split decision. [ABSTRACT FROM AUTHOR]

An FDA panel has narrowly backed the approval of Mallinckrodt's terlipressin for a type of kidney failure. The 8-7 vote comes after FDA staffers flagged multiple concerns for the drug, including whether meeting the surrogate endpoint in its phase 3 study actually translated to patients living longer or faring better. [ABSTRACT FROM AUTHOR]

Mallinckrodt unveiled phase 3 data in November showing its rare disease med terlipressin beat placebo at reversing a type of kidney failure. An FDA panel will convene on Wednesday to help the agency decide the drug's fate—and their key question will be about the study's surrogate endpoint. [ABSTRACT FROM AUTHOR]

2019 will likely go down as a landmark year for biopharma partnering, at least when looking at the sums involved. [ABSTRACT FROM AUTHOR]

The FDA has issued a complete response letter to Mallinckrodt’s jaundice drug stannsoporfin. Mallinckrodt plans to talk to the FDA in the coming months before deciding the fate of a drug it acquired in an $80 million buyout last year. [ABSTRACT FROM AUTHOR]